Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2750
-0.0143 (-4.94%)
At close: Nov 19, 2026, 4:00 PM EST
0.2870
+0.0120 (4.36%)
After-hours: Nov 19, 2026, 7:30 PM EST
Mereo BioPharma Group Revenue
Mereo BioPharma Group had revenue of $800.00K in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to $800.00K, up 60.00% year-over-year. In the year 2025, Mereo BioPharma Group had annual revenue of $500.00K.
Revenue (ttm)
$800.00K
Revenue Growth
+60.00%
P/S Ratio
57.26
Revenue / Employee
$20,513
Employees
39
Market Cap
43.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 500.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.00M |
| MindWalk Holdings | 11.57M |
| ImageneBio | 800.00K |
| Clene | 238.00K |
| MiNK Therapeutics | 200.00K |
MREO News
- 10 days ago - Mereo BioPharma Group Releases Q3 2026 Financial Results - AlphaStreet
- 10 days ago - Mereo BioPharma Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 3 months ago - JPMorgan downgrades Mereo to Underweight on regulatory uncertainty - TheFly
- 3 months ago - Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan - TheFly
- 3 months ago - Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 - Nasdaq
- 3 months ago - Mereo BioPharma Group Releases Q2 2026 Financial Results - AlphaStreet
- 3 months ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq
- 3 months ago - Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights - GlobeNewsWire